NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease

Reuters

2025/09/09

<a href="https://laohu8.com/S/NNVC">NanoViricides Inc.</a> Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease

NanoViricides Inc., a clinical-stage company known for developing broad-spectrum antiviral drugs, has announced that it will be presenting updates on its drug pipeline, platform technologies, and new clinical developments at the Life Science Executive Partnering Congress in Boston on September 17, 2025. The presentation will be led by Anil R. Diwan, PhD, President and Executive Chairman of the company. Among the highlights is their most advanced candidate, NV-387, an ultra-broad-spectrum antiviral targeting multiple respiratory human pathogenic viruses. Additionally, the company will discuss its clinical-ready pan-herpesvirus drug candidate, NV-HHV-1, and its anti-HIV drug candidate, NV-HIV-1. These developments will be presented at the event, indicating that the results are yet to be formally disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1070576) on September 09, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2566697128"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566697128\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566697128?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566697128","market":"fut","top_or_hot":-1,"title":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NanoViricides Inc., a clinical-stage company known for developing broad-spectrum antiviral drugs, has announced that it will be presenting updates on its drug pipeline, platform technologies, and new clinical developments at the Life Science Executive Partnering Congress in Boston on September 17, 2025. The presentation will be led by Anil R. Diwan, PhD, President and Executive Chairman of the company. Among the highlights is their most advanced candidate, NV-387, an ultra-broad-spectrum antiviral targeting multiple respiratory human pathogenic viruses. Additionally, the company will discuss its clinical-ready pan-herpesvirus drug candidate, NV-HHV-1, and its anti-HIV drug candidate, NV-HIV-1. These developments will be presented at the event, indicating that the results are yet to be formally disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1070576) on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-09 20:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NanoViricides Inc., a clinical-stage company known for developing broad-spectrum antiviral drugs, has announced that it will be presenting updates on its drug pipeline, platform technologies, and new clinical developments at the Life Science Executive Partnering Congress in Boston on September 17, 2025. The presentation will be led by Anil R. Diwan, PhD, President and Executive Chairman of the company. Among the highlights is their most advanced candidate, NV-387, an ultra-broad-spectrum antiviral targeting multiple respiratory human pathogenic viruses. Additionally, the company will discuss its clinical-ready pan-herpesvirus drug candidate, NV-HHV-1, and its anti-HIV drug candidate, NV-HIV-1. These developments will be presented at the event, indicating that the results are yet to be formally disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1070576) on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDLGxgs8:1","article_id":"2566697128","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566697128","pubTimestamp":1757421812,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NanoViricides Inc., a clinical-stage company known for developing broad-spectrum antiviral drugs, has announced that it will be presenting updates on its drug pipeline, platform technologies, and new clinical developments at the Life Science Executive Partnering Congress in Boston on September 17, 2025. The presentation will be led by Anil R. Diwan, PhD, President and Executive Chairman of the company. Among the highlights is their most advanced candidate, NV-387, an ultra-broad-spectrum antiviral targeting multiple respiratory human pathogenic viruses. Additionally, the company will discuss its clinical-ready pan-herpesvirus drug candidate, NV-HHV-1, and its anti-HIV drug candidate, NV-HIV-1. These developments will be presented at the event, indicating that the results are yet to be formally disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NNVC":"NanoViricides Inc.","BK4568":"美国抗疫概念"},"translate_title":"NanoViricides Inc.宣布针对MPOX疾病的广谱抗病毒NV-387进行II期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NNVC":0.9},"content_text":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease\n    \n\n        NanoViricides Inc., a clinical-stage company known for developing broad-spectrum antiviral drugs, has announced that it will be presenting updates on its drug pipeline, platform technologies, and new clinical developments at the Life Science Executive Partnering Congress in Boston on September 17, 2025. The presentation will be led by Anil R. Diwan, PhD, President and Executive Chairman of the company. Among the highlights is their most advanced candidate, NV-387, an ultra-broad-spectrum antiviral targeting multiple respiratory human pathogenic viruses. Additionally, the company will discuss its clinical-ready pan-herpesvirus drug candidate, NV-HHV-1, and its anti-HIV drug candidate, NV-HIV-1. These developments will be presented at the event, indicating that the results are yet to be formally disclosed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1070576) on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}